Inner Compass · Clinical Research

The peer-reviewed science behind Inner Compass.

Six published studies — including one meta-analysis of 1,002 participants. Three biological systems. One transparent reference document for women who want to read the science before they trust the formula.

6 Published studies
3 Biological systems
4 RCTs + 1 meta-analysis
2005-2022 Span covered
Why we publish this

Most botanical brands cite "adaptogen." We show our work.

The adaptogen industry runs on heritage language — "traditionally used," "ancient remedy," "clinically researched." Words that signal credibility without taking the risk of being checked. We chose the opposite approach.

Every botanical at the center of Inner Compass was selected with reference to published research. This page exists so you can read it too. Every study below is linked directly to PubMed — the same primary sources used by clinicians, researchers, and integrative MDs.

These studies are about individual botanicals or biological mechanisms — not about Inner Compass itself. We do not yet have a randomized clinical trial of the finished formula, and we will not pretend otherwise.

What you'll find on this page

Three biological systems. One transparency section. Read in order or jump to what matters to you.

01

Cortisol & HPA-axis recovery — the mechanical center.

The hypothalamic-pituitary-adrenal (HPA) axis is the body's stress-response circuit. Under chronic load, it doesn't fail — it learns to stay activated. Cortisol rhythms flatten, recovery windows lengthen, and the gap between effort and baseline gets wider. The literature on adaptogens — ashwagandha first among them — examines whether targeted botanical compounds can measurably shorten that gap. This is the mechanical center of Inner Compass.

Indian J Psychol Med · 2012 · Double-blind RCT · N = 64

Safety and efficacy of high-concentration full-spectrum ashwagandha root extract in reducing stress and anxiety in adults.

Chandrasekhar K, Kapoor J, Anishetty S.

Population

64 adults with a history of chronic stress. Mean age ~30s-40s. 60-day trial period.

Method

Prospective randomized double-blind placebo-controlled trial. 300 mg high-concentration full-spectrum ashwagandha root extract twice daily for 60 days vs placebo. Outcomes: PSS (Perceived Stress Scale), DASS, GHQ-28 (General Health Questionnaire), serum cortisol.

Key findings

Statistically significant reduction across all stress scales in the ashwagandha group vs placebo (p<0.0001) at Day 60. Serum cortisol substantially reduced (p=0.0006). Mild and comparable adverse-event profile between groups.

Limitations & context

Single-site trial. The proprietary extract used (KSM-66) may not generalize to all ashwagandha products. Placebo response in stress-scale endpoints is typically large, though dose-resolved cortisol change adds objective signal.

Why this matters for Inner Compass: This is the foundational modern RCT establishing ashwagandha's measurable effect on the HPA axis. Inner Compass uses ashwagandha root extract as the central botanical in its cortisol-recovery system specifically because of the converging evidence this trial helped establish.

View on PubMed
Medicine (Baltimore) · 2019 · Double-blind RCT · N = 60

An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract.

Lopresti AL, Smith SJ, Malvi H, Kodgule R.

Population

60 stressed but otherwise healthy adults, mean age 30s-40s. 60-day intervention period.

Method

Randomized double-blind placebo-controlled trial. 240 mg of a standardized ashwagandha extract (Shoden) once daily vs placebo. Outcomes: Hamilton Anxiety Rating Scale (HAM-A), DASS-21, and hormone profile (morning cortisol, DHEA-S, testosterone).

Key findings

Statistically significant reduction in HAM-A score (p=0.040), morning cortisol (p<0.001), and DHEA-S (p=0.004) in ashwagandha vs placebo. Near-significant DASS-21 reduction (p=0.096). No adverse events reported.

Limitations & context

Modest sample (N=60). 240 mg dose is on the lower end of clinical doses; effect size may differ at higher doses. The Shoden extract is a specific commercial preparation — extrapolation to other ashwagandha extracts requires caution.

Why this matters for Inner Compass: Provides hormone-resolved evidence: ashwagandha doesn't just shift subjective stress scores, it measurably modulates HPA-axis output (cortisol & DHEA-S). This is the mechanistic basis for including ashwagandha at the center of Inner Compass.

View on PubMed
Phytotherapy Research · 2022 · Systematic review + meta-analysis · N = 12 RCTs / 1,002

Does ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A systematic review and meta-analysis of RCTs.

Akhgarjand C, Asoudeh F, Bagheri A, Kalantar Z, Vahabi Z, Shab-Bidar S, Djafarian K.

Population

12 eligible RCTs, pooled N=1,002 participants, age range 25-48 years. Search through December 2021.

Method

Systematic review (PubMed/Medline, Scopus, Google Scholar) of RCTs examining ashwagandha extract on anxiety and stress. Random-effects model with standardized mean difference (SMD) as pooled effect estimate.

Key findings

Significant pooled reduction in anxiety (SMD = -1.55, 95% CI: -2.37 to -0.74; p=0.005) and stress (SMD = -1.75, 95% CI: -2.29 to -1.22; p=0.005). Effect direction consistent across studies; magnitude robust.

Limitations & context

High heterogeneity (I²=93.8% for anxiety, 83.1% for stress) — extracts, doses, and populations vary across included trials. Publication bias is a known issue in the botanical-supplement literature. Authors recommend cautious interpretation of pooled effect sizes.

Why this matters for Inner Compass: Most rigorous synthesis of ashwagandha's stress-modulating effects to date. Even applying conservative methodological skepticism, the directional signal across 12 RCTs is consistent — and that's the standard a botanical needs to clear to anchor a recovery formula.

View on PubMed
02

Female sexual wellbeing — non-hormonal pathways.

Sexual desire and response are tightly coupled to recovery. When the cortisol-driven 'always-on' state takes over, libido fades — not as a personal failure, but as a measurable downstream consequence of HPA-axis dysregulation. The literature on Maca (Lepidium meyenii) examines a specific non-hormonal pathway: improving sexual function and psychological symptoms without changing estrogen, FSH, LH, or testosterone. That is the precise mechanism Inner Compass needs.

Menopause · 2008 · Double-blind RCT (crossover) · N = 14

Beneficial effects of Lepidium meyenii (Maca) on psychological symptoms and measures of sexual dysfunction in postmenopausal women are not related to estrogen or androgen content.

Brooks NA, Wilcox G, Walker KZ, Ashton JF, Cox MB, Stojanovska L.

Population

14 postmenopausal women, randomized double-blind placebo-controlled crossover trial (12 weeks total: 6 weeks Maca, 6 weeks placebo, alternating order).

Method

3.5 g/day powdered Maca vs matched placebo. Blood draws at baseline, week 6, week 12 for estradiol, FSH, LH, SHBG. Greene Climacteric Scale used to assess menopause-related symptom severity and sexual dysfunction.

Key findings

Significant reduction in psychological symptoms (anxiety, depression) and measures of sexual dysfunction in the Maca phase vs placebo. Crucially: no significant changes in serum estradiol, FSH, LH, or SHBG. The benefit is non-hormonal.

Limitations & context

Small sample (N=14). Specific to postmenopausal population — generalization to premenopausal women requires additional trials. Symptom scales are self-reported.

Why this matters for Inner Compass: This is the cleanest demonstration that Maca's effect on sexual wellbeing operates through a non-hormonal pathway. Inner Compass includes Maca specifically because high-performing women cannot afford a formula that disrupts their hormonal axis — they need recovery support that works around it.

View on PubMed
BMC Complement Altern Med · 2010 · Systematic review · N = 4 RCTs

Maca (L. meyenii) for improving sexual function: a systematic review.

Shin BC, Lee MS, Yang EJ, Lim HS, Ernst E.

Population

Systematic review of 4 randomized controlled trials of Maca for sexual function in mixed populations: healthy adults, postmenopausal women, men with mild ED, and women with SSRI-induced sexual dysfunction.

Method

Literature search of 17 databases through May 2010. Inclusion criteria: RCT design, Maca intervention, sexual function as outcome. Two reviewers independently extracted data; methodological quality assessed.

Key findings

Evidence suggests Maca improves sexual function in both clinical (SSRI-induced sexual dysfunction, postmenopausal sexual dysfunction) and healthy populations. Effect size more consistent in clinical populations than in healthy subjects. Tolerability profile good across trials.

Limitations & context

Only 4 RCTs available at the time of review — small evidence base. Heterogeneous Maca preparations across trials. Calls for larger, longer trials with standardized extracts.

Why this matters for Inner Compass: Confirms that the signal supporting Maca is not a single trial — it's repeated across independent studies in multiple populations. That convergence is what justifies Maca's inclusion in Inner Compass as more than a traditional-use ingredient.

View on PubMed
03

Cognitive recovery — closing the mental-fatigue gap.

Among the symptoms of the Performance Recovery Gap, cognitive fatigue is often the most disabling: the mental haze that lingers the day after a demanding output, the slow start that doesn't recover by mid-morning. Panax ginseng is the most directly studied botanical for this exact endpoint — measurable cognitive performance during sustained mental demand. Inner Compass includes ginseng for the gap between mental peak effort and next-day clarity.

J Psychopharmacol · 2005 · Double-blind RCT (crossover) · N = 30

Single doses of Panax ginseng (G115) reduce blood glucose levels and improve cognitive performance during sustained mental activity.

Reay JL, Kennedy DO, Scholey AB.

Population

30 healthy young adults, double-blind placebo-controlled balanced crossover design.

Method

Three conditions (placebo, 200 mg G115 ginseng, 400 mg G115), 60 min pre-task. Six successive 10-min cognitive batteries (Serial Threes, Serial Sevens, RVIP, mental-fatigue VAS) to induce sustained mental load.

Key findings

200 mg ginseng produced significant improvements in Serial Sevens subtraction accuracy and significantly reduced subjective mental fatigue across the demanding-task battery (p<0.05). Effect linked partly to ginseng's gluco-regulatory properties during sustained cognitive demand.

Limitations & context

Acute single-dose study — long-term cumulative effects not measured. Healthy young-adult population — extrapolation to women 35-55 (Inner Compass's primary user) is partial. Glycemic mechanism may interact with feeding state.

Why this matters for Inner Compass: Demonstrates that Panax ginseng produces a measurable, dose-resolved effect on the exact symptom Inner Compass targets: mental fatigue during sustained cognitive output. Ginseng is included in the formula at clinically-relevant levels for this mechanism specifically.

View on PubMed
Radical transparency

What these studies don't — and can't — tell you.

Most studies referenced on this page tested specific botanicals — at specific doses, of specific extracts — in isolation. Inner Compass is a 24-ingredient formula. The combined effect of the complete formula has not been measured in a randomized trial of the finished product — and we will not claim otherwise.

On extract identity: botanical research is highly extract-specific. KSM-66 ashwagandha (used by Chandrasekhar 2012) is not interchangeable with any other ashwagandha extract — withanolide content, root vs leaf, full-spectrum vs isolate all matter. Inner Compass uses well-documented species and extract forms, but where the published literature tests a specific commercial extract, we do not claim that exact extract is in our formula unless explicitly noted on our COA.

On sample sizes: the foundational ashwagandha trials are small (N=14 to N=64). The 2022 meta-analysis aggregates 12 studies for 1,002 participants — that is the size of the evidence base. It is substantial enough to suggest a real effect, narrow enough that we describe it as 'evidence-informed,' not 'clinically proven.'

This level of disclosure is unusual in the botanical-supplement industry. We think that's a problem worth fixing.

From research to formula

How this research informs Inner Compass's design.

The choice to anchor Inner Compass around ashwagandha — and not around a more flashy single-mechanism ingredient — reflects the convergence of the cortisol-modulation evidence: foundational RCTs (Chandrasekhar 2012, Lopresti 2019) plus a 1,002-participant meta-analysis pointing in the same direction. That convergence is the standard a central ingredient should meet.

The non-hormonal sexual-wellbeing pathway (Brooks 2008, Shin 2010) directly shaped the design philosophy: Inner Compass had to support recovery — including libido — without disturbing the hormonal axis of women already managing demanding lives. Maca was chosen specifically for this mechanism.

Panax ginseng addresses the cognitive-fatigue component of recovery — measurable in sustained mental-demand tasks (Reay 2005). The other 21 ingredients support, complement, or extend these three central mechanisms. We do not promise outcomes. We promise alignment between what the evidence supports and what the bottle contains.

Ready to start?

Inner Compass: a 24-ingredient botanical formula for the Performance Recovery Gap.

Cortisol-recovery support. Non-hormonal sexual wellbeing. Cognitive clarity. Built on the research above.

Discover Inner Compass

These statements have not been evaluated by the Food and Drug Administration. Inner Compass is not intended to diagnose, treat, cure or prevent any disease. The research referenced on this page concerns individual botanical compounds or biological mechanisms, not the Inner Compass finished formula. Botanical effects can be highly extract- and dose-specific. Always consult a qualified healthcare provider before starting any supplement, especially during pregnancy, while breastfeeding, or if you are managing a chronic condition or taking medication.